FLT3 and acute leukemia: Given the importance of both the activation loop and SHP2 in FLT3-ITD-mediated transformation, the development of drugs that interfere with binding of SHP2 to Y842 or with the activity of SHP2 could be useful drugs for the treatment of patients with acute leukemia.